MC0518

BIOLOGICAL4 trials

Sponsors

Medac Gesellschaft fuer klinische Spezialprapaerate mbH, medac GmbH

Conditions

Steroid refractory Acute Graft versus host DiseaseSteroid-refractory Acute Graft-versus-host Disease

Phase 2

A Randomised, Open label, Controlled, Multicentre, Phase 2 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants with Steroid refractory Acute Graft versus host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

RecruitingCTIS2023-503952-28-00

Medac Gesellschaft fuer klinische Spezialprapaerate mbHSteroid refractory Acute Graft versus host Disease

Start: 2023-11-13Target: 54Updated: 2025-05-21

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Active, not recruitingNCT06075706

medac GmbHSteroid-refractory Acute Graft-versus-host Disease

Start: 2023-11-13End: 2031-06-01Target: 48Updated: 2026-01-27

Phase 3

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

RecruitingNCT04629833

medac GmbHSteroid-refractory Acute Graft-versus-host Disease

Start: 2021-08-16End: 2030-08-31Target: 210Updated: 2025-08-13

A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)

RecruitingCTIS2023-505737-26-00

Medac Gesellschaft fuer klinische Spezialprapaerate mbHSteroid refractory Acute Graft versus host Disease

Start: 2020-07-22Target: 210Updated: 2025-12-18